Logo

Pioneering a New Era in Personalized Antibiotic Therapy

SeLux Analyzer Incoulatoir

About SeLux Diagostics

SeLux Diagnostics is developing a Next Generation Phenotyping (NGP) platform that promises to transform infectious disease patient treatment by dramatically increasing the speed and accuracy with which targeted, personalized antibiotic therapies can be prescribed. Earlier, better-informed treatment decisions will save lives, improve patient outcomes, decrease hospital lengths of stay and hospital acquired infections, and help combat the global antibiotic resistance epidemic.

The CDC has cited bacterial resistance to antibiotics among the world’s deadliest and costliest health threats. Using current technologies, doctors must overprescribe powerful, broad-spectrum antibiotics for days while waiting for key diagnostic results to direct personalized therapy. SeLux NGP is the only platform capable of delivering personalized therapy results for all patients within a day of hospital entry, speeding this targeted treatment by an average of 2 days and as many as 4 days for patients infected with multi-drug resistant organisms.

SeLux Diagnostics was founded in 2014 by two Yale- and Harvard-trained engineers working in an improvised attic laboratory. By 2018, SeLux’s phenotypic test had garnered the recognition and support of the National Institute of Health and Biomedical Advanced Research and Development Authority for the technology’s promising impact, advancing through the Series B round of funding that will allow them to complete product development and perform the clinical trials required to gain FDA clearance.

On September 25, 2018, the company announced that it had signed a milestone-based contract worth up to $45 million with the Biomedical Advanced Research and Development Authority (BARDA), a division of the U.S. Department of Health and Human Services’ (HHS) Office of the Assistant Secretary for Preparedness and Response (ASPR).

SeLux immediately receives $9.3 million from BARDA to fund the clinical trial necessary for SeLux NGP, SeLux's next-generation phenotyping platform. The additional $36 million will fund the development of SeLux's second-generation rapid sepsis diagnostic system.

SeLux has also raised $25 million in Series B financing to support the pivotal FDA trial for SeLux’s next-generation phenotyping (NGP) platform. The round was led by Sands Capital Ventures and included returning investors RA Capital and Schooner Capital and new investors Sands Capital and Northpond Ventures. This funding positions SeLux to complete development and perform the clinical trial necessary to gain FDA clearance.

SeLux Diagnostics is based in Boston, Massachusetts.

SeLux process timeline

Technology

SeLux’s Next Generation Phenotyping (NGP) platform provides rapid, high-throughput, fully-automated AST results, enabling same-shift susceptibility testing of up to 50 antibiotics in parallel. The platform is driven by SeLux’s proprietary assay, which differentiates antibiotic-induced bacterial growth modes with a surface-binding fluorescent amplifier. By elucidating bacterial morphologies, SeLux NGP makes antibiotic susceptibility determinations two to four times faster than current state-of-the-art, high-throughput AST technologies, which require 24+ hours from patient sample to AST results. And while some emerging technologies claim to deliver results at speeds comparable to SeLux, those entrants require complicated systems with quite narrow testing menus.

The SeLux technology delivers same-shift AST results for the vast majority of non-fastidious pathogens. What’s more, SeLux leverages standard equipment to make adoption easy across labs. The combination of unparalleled early detection, vast antibiotic test menus, and cost-effective implementation positions SeLux NGP as the platform of choice for integrated delivery networks, academic medical centers, and other healthcare providers that want to transform the treatment of patients with infectious disease. SeLux NGP breaks the speed versus complexity tradeoff inherent in current AST models, dramatically improves outcomes for patients, reduces patient length of stay and pharmacy costs for health systems and contributes towards greater Antibiotic Stewardship worldwide.


SeLux process timeline

SeLux process timeline

Features & Benefits

Next-Day Personalized Antibiotic Therapy for Most Patients

Faster Personalized Therapies

SeLux’s Next-Generation Phenotyping (NGP) platform will enable physicians to transition patients to personalized antibiotic therapies much more quickly – from one to four days earlier – than current state-of-the-art platforms, providing next-day personalized therapies for nearly all patients.

Unparalleled Early Detection

SeLux NGP detects antibiotic effects on bacteria more rapidly and at lower concentrations than currently possible. This enables bacterial susceptibilities to different antibiotics to be determined virtually simultaneously to the identification of the infecting bacteria.

Same-Day Results

SeLux’s second-generation platform will deliver same-day personalized therapy results for patients with bacteremia, septicemia, and urinary tract infections. The platform obviates the need for traditional blood and agar cultures by utilizing SeLux NGP’s speed and accuracy.

Works for Broad Menu of Pathogens

SeLux’s technology works across a vast menu of bacteria and fungi, delivering an unmatched breadth of AST results to labs. The initial product will focus on the major non-fastidious bacterial pathogens and later upgrades will add fastidious bacteria and fungi.

No Antibiotic Limitations

SeLux NGP provides a menu of 50+ antibiotics per sample -- 5X more antibiotics than current AST technology -- and, due to its ready expansion room, will seamlessly incorporate newly-approved drugs.

Works For All Samples

Since effective antibiotic stewardship requires all patients to be rapidly transitioned to targeted therapies, SeLux’s first product is designed to provide rapid results from isolates deriving from all sample types.


Standard Workflow

SeLux NGP leverages standard microbiology processes so it can easily integrate into clinical microbiology laboratories to rapidly improve antibiotic susceptibility testing efficiencies and speed.

High Throughput

One SeLux system will deliver over 100 AST tests per day, matching standard laboratory susceptibility exceeding the workflow needs of labs.



Sensible ROI

Designed for frictionless integration in existing labs, SeLux’s breakthrough technology promises superior return on investment to health systems by reducing pharmacy costs, patient length of stay, Hospital Acquired Conditions (HAC), and HAC reduction penalties.



SeLux process timeline

Team

Steve Lufkin

index.html
Hide

STEVE LUFKIN

TBD.

CEO

Eric Stern, PhD

Hide

ERIC STERN

Eric Stern, SeLux co-founder and CTO and acting CEO, has over 20 years of R&D experience and 9+ years leading industrial R&D teams. He has has led the development 1 commercially-available product and 2 projects currently in late-stage commercial development. He has published over 25 peer-reviewed papers, including first-author publications in Nature, Nature Materials, and Nature Nanotechnology, has 13 granted and pending patents, and 11 active provisionals. He earned a B.S. degree in Chemistry, a M.S. degree in Electrical Engineering, and a Ph.D. in Biomedical Engineering from Yale University and performed postdoctoral research at Harvard University before entering industry. When not working or playing with his growing family, he’s generally asleep or stuck in traffic.

CTO & Co-founder

Aleksandar Vacic, PhD

Hide

ALEKSANDAR VACIC, PhD

Aleksandar Vacic is the President and co-founder of SeLux. His primary leadership role at SeLux is engineering and product development. As an applied physicist and electrical engineer, Alek believes that both strong theoretical foundations and hands-on practical insights must be exploited to commercialize novel technologies. He enjoys working with multidisciplinary teams solving complex problems. His work has spanned semiconductors, plasma engineering, optics, optoelectronics, bioelectronics, Monte Carlo simulations, and numerical algorithms.

Previously, he led the Cell Processing team at 1366 Technologies where he transferred processes to customer manufacturing sites in Asia and Europe, and developed a plasma texturing process for high efficiency solar cells.

While at Yale he developed fabrication and design methods to improve yield and reliability of nanoscale biosensors including the understanding of semiconductor-biomolecule interaction which resulted in a novel calibration and quantification methodology. He has 2 granted, 1 licensed, and 10 pending patents and provisional applications. He earned his PhD from Yale and Dipl.-Ing. (5 year) in Technical Physics from the School of Electrical Engineering in Belgrade (Serbia) as Valedictorian (Class of 600+). While at Yale he was awarded the Best Presentation award at the Nanodevices for Defense and Security Conference 2009 and Yale College Prize Teaching Fellowship. When not solving difficult problems, Alek enjoys travelling, cooking and running with his awesome spouse, Yi-Wen.

President & Co-founder

Benjamin Spears, PhD

Hide

BENJAMIN SPEARS, PhD

Ben joined SeLux in the fall of 2015 as the Senior Research Chemist and his work is focused on the development of amplification technologies for the advancement of high sensitivity assay platforms. Ben has more than 8 years of interdisciplinary experience, centered around polymer chemistry, which encompasses nanoparticle, hydrogel, and bioconjugate formation. From this work, Ben has developed knowledge of all stages of polymer research, from conception and synthesis of starting materials, to polymer formation and utilization, including appropriate corresponding characterization. Ben received his PhD from Vanderbilt University where he pioneered the development of several novel methods utilizing polymers he conceived and synthesized while simultaneously developing external collaborations with multiple labs. Ben’s work has led to multiple publications, patents, and presentations.

Lead Scientist

Nathan Purmort, MSEE

Hide

NATHAN PURMORT, MSEE

Nate joined SeLux early in 2016 and with over 10 years in industry, he brings a breadth of engineering and medical product development experience to the team. Prior to SeLux he was at DEKA R&D where he worked as an FPGA Architect, Systems Engineer, and Electrical Engineering team lead. In these roles Nate worked with Fortune 500 clients and contractors and managed aspects of the manufacturing transfer of 3 mid-high volume class 2 medical devices – all of which received FDA 510(k) clearance. Nate also previously worked as an embedded software engineer in public safety technology and holds a BS and MS in Electrical Engineering from the University of New Hampshire.

Principal Engineer

Felicia Giok, MSc

Hide

FELICIA GIOK, MSc

Felicia joined the SeLux Diagnostics team in August 2016 as a scientist after graduating from Kansas State University with her MSc. She has 2+ years of experience in antibiotic susceptibility testing (AST), with hands-on experience in various techniques in R&D and laboratory settings. Her research work at KSU included profiling antibiotic resistance in different beneficial bacterial strains used in direct-fed microbials (DFMs) and observing for transfer of resistance between the strains, specifically Enterococcus faecium. She presented her research at two oral presentations: the American Society of Animal Science Midwest Meeting (2016) in Des Moines, IA and the K-State Graduate Research, Arts, and Discovery Forum (2016) at KSU. Her expertise also covers genetic profiling of these strains and characterization of clinically important bacterial strains. She enjoys amassing various skills and is currently dipping her toes in early stage computer programming. Prior to her graduate work, she was part of a wonderful spay/neuter clinic team of animal lovers, helping companion animals to find loving homes.

Scientist

Kelly Flentie, PhD

Hide

KELLY FLENTIE, PhD

Kelly joined SeLux Diagnostics in 2016 as the Senior Microbiologist. Kelly brings more than 15 years of multidisciplinary investigative experience in microbiology, antimicrobial drug development, imaging technologies, and high-throughput screening to the team. Kelly earned her Ph.D. at Washington University in St. Louis investigating interactions between Salmonella and cancer cells, with an emphasis on characterizing bacterial behaviors that could be coopted for novel cancer treatment or diagnostic strategies. Her postdoctoral research focused on stress tolerance mechanisms in Mycobacterium tuberculosis and identifying novel antimicrobials to target this pathogen. Her work has led to multiple peer-reviewed journal articles, a pending patent, a Principle Investigator pilot project grant award, and selection for an oral presentation at a Gordon conference on Tuberculosis drug development.

Lead Scientist

Sarah Scott, BSChE

Hide

SARAH SCOTT, BSChE

Sarah Scott joined the SeLux team in April 2017. As a Senior Engineer, Sarah leads the implementation of the Quality Management System at SeLux. Sarah brings more than half a decade of experience in process development and pharmaceutical manufacturing. At contract manufacturing organization Albany Molecular Research Incorporated, Sarah worked as a Process Engineer. In this role, she led the manufacture of several early-stage clinical products. Prior to joining SeLux, Sarah served as the Director of Manufacturing at PixarBio Corporation. There she led the company’s transition from process development to manufacturing. Sarah holds a B.S. in Chemical Engineering from Northeastern University.

Senior Engineer

Kayla DaPonte, MLS(ASCP)CM

Hide

KAYLA DAPONTE, MLS (ASCP)CM

TBD.

Scientist

Derek Puff, PhD

Hide

DEREK PUFF, PhD

As the Principal Software Developer, Derek is responsible for the design and implementation of the software architecture for the SeLux Diagnostics AST platform. <\P>

Derek has over 20 years of experience in the medical imaging, biotech, and immunotherapy industries. Prior to joining SeLux Diagnostics, he was Principal Software Developer at the Waltham site for Juno Therapeutics, a Seattle-based immunotherapy company. At Juno, he built a suite of data storage, processing, and analysis tools to enable identification of lead candidates in the Juno antibody discovery platform. Previously, Derek was Director of Software Engineering at SRU Biosystems, where he developed data acquisition and analysis capabilities for their label-free detection platform for small molecule and protein binding assays. He began his career with Picker Medical Systems (now Philips Healthcare), working on visualization of dose distributions for their AcQSim™ radiation therapy treatment planning software.

Principal Software Engineer

Frederick Floyd Jr.

Hide

FRED FLOYD

TBD.

Lead Engineer

Vamsee Pasangulapati BSCS

Hide

VAMSEE PASANGULAPATI BSCS

TBD.

Senior Software Engineer

Beth Bauman, MSME

Hide

BETH BAUMAN, MSME

TBD<\P>

Director of Operations

Andrew Reynolds, BSBME

Hide

ANDREW REYNOLDS, BSBME

TBD<\P>

Senior Systems Engineer

Kenny Varner, MSBME MSETIM

Hide

KENNY VARNER, MS(BME+ETIM)

TBD<\P>

V&V Engineer

Board of Directors

Scott Yaphe

Parker Cassidy

Steve Lufkin

Eric Stern

Mike Rubin


Investors & Partners


Granting Agencies



SeLux process timeline

Newsroom

Careers

SeLux’s interdisciplinary team has expertise in microbiology, biochemistry, chemistry, engineering, software, and algorithm design and is buttressed by distinguished experts in Clinical Microbiology, Infectious Disease, and Machine Learning. We are always looking for innovative scientific, engineering, marketing, and business development talent.

How to find us

SeLux Diagnostics, Inc

56 Roland Street, Suite 206

Charlestown, MA 02129

+1-617-945-9383

Info [AT] SeLuxDX [.] com